IDiyas

For the Inventor, By the Inventor

Mannheim-Waldhof, Germany

Kurt Stach

USPTO Granted Patents = 27

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 175(Granted Patents)


Location History:

  • Mannheim, DE (1976)
  • Mannheim-Waldhof, DE (1976 - 1984)

Company Filing History:

goldMedal27 out of 1,164 
 
Boehringer Mannheim Gmbh
 patents

Years Active: 1976-1984

Loading Chart...
27 patents (USPTO):Explore Patents
1. 4436742 - 4-Hydroxy-2,1,3-benzthiadiazole compounds and .beta.-adrenergic method (1984-03-13),
2. 4152446 - Aminopropanol compounds and compositions for the treatment of cardiac (1979-05-01),
3. 4076829 - Aminopropanol compounds and compositions for the treatment of cardiac (1978-02-28),
4. 4049811 - Compositions using cycloalkano-quinolone derivatives and their method of (1977-09-20),
5. 4029783 - N-substituted 1-amino-3-phenoxy-propan-2-ol compounds and therapeutic (1977-06-14),
6. 4017539 - Biguanide compounds and anti-diabetic compositions (1977-04-12),
7. 4006141 - Nitroimidazolyl-triazolo-pyridazine compounds (1977-02-01),
8. 3998810 - N-substituted 1-amino-3-phenoxy-propan-2-ol compounds and therapeutic (1976-12-21),
9. 3997667 - 1-[3-(Naphth-1-yloxy)-propyl]-piperazine compounds and therapeutic (1976-12-14),
10. 3997666 - 1-[3-(Naphth-1-yloxy)-2-hydroxypropvl]-piperazine compounds and (1976-12-14),
11. 3996241 - 2-Hydroxymethyl indole compounds and blood sugar lowering compositions (1976-12-07),
12. 3995040 - Cyclopenteno-3-carboxyl-4-quinolone derivatives and their bacteriostatic (1976-11-30),
13. 3991188 - 3-Alkyl-4-sulfamoyl-aniline therapeutic compositions (1976-11-09),
14. 3989832 - Combating bacteria with nitroimidazolyl-triazolo-pyridiazine compounds (1976-11-02),
15. 3988317 - Heterocyclic-substituted nebularin compounds (1976-10-26),

Title: The Innovative Contributions of Kurt Stach in Cardiac and Circulatory Health

Introduction: Kurt Stach, a notable inventor hailing from Mannheim-Waldhof, Germany, has made significant advancements in the field of pharmacology. With a remarkable portfolio of 27 patents, his work primarily focuses on innovative compounds that play a critical role in heart health and circulation.

Latest Patents: Among his latest inventions are the patents for "4-Hydroxy-2,1,3-benzthiadiazole compounds" and the "β-adrenergic method." The first patent discusses new amine derivatives of 4-hydroxy-2,1,3-benzthiadiazoles, which exhibit marked effects as inhibitors of adrenogenic β-receptors. This makes them particularly useful for the treatment and prophylaxis of cardiac and circulatory diseases. Additionally, his work on "Aminopropanol compounds and compositions for the treatment of cardiac" introduces new aminopropanol compounds, demonstrating promising potential in enhancing heart health.

Career Highlights: Kurt Stach has worked at Boehringer Mannheim GmbH, a prominent biotechnology company that emphasizes research and development of pharmaceuticals aimed at improving patient health. His innovative approach has led to advancements that impact not only scientific research but also practical applications in medicine.

Collaborations: In his pursuit of excellence, Kurt has collaborated with esteemed colleagues such as Max Thiel and Egon Roesch. Their combined expertise has driven successful projects that contribute to the understanding and advancement of cardiac treatments, fostering a collaborative spirit in the field.

Conclusion: Kurt Stach's contributions to pharmacology, particularly in cardiac health, are documented through his numerous patents and collaborative efforts. His dedication to innovation presents a promising future for treatments of cardiovascular diseases, highlighting the essential role of inventors in medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…